These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 3875612)

  • 1. Cleavage of human high molecular weight kininogen by factor XIa in vitro. Effect on structure and function.
    Scott CF; Silver LD; Purdon AD; Colman RW
    J Biol Chem; 1985 Sep; 260(19):10856-63. PubMed ID: 3875612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of the coagulant activity and surface binding of high molecular weight kininogen.
    Colman RW; Silver LD; Purdon AD; Chang JJ; Scott CF
    Trans Assoc Am Physicians; 1984; 97():113-23. PubMed ID: 6336014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conformation of high molecular weight kininogen: effects of kallikrein and factor XIa cleavage.
    Villanueva GB; Leung L; Bradford H; Colman RW
    Biochem Biophys Res Commun; 1989 Jan; 158(1):72-9. PubMed ID: 2783551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cleavage of human high-molecular weight kininogen by purified kallikreins and upon contact activation of plasma.
    Reddigari S; Kaplan AP
    Blood; 1988 May; 71(5):1334-40. PubMed ID: 2451949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cleavage of human high molecular weight kininogen markedly enhances its coagulant activity. Evidence that this molecule exists as a procofactor.
    Scott CF; Silver LD; Schapira M; Colman RW
    J Clin Invest; 1984 Apr; 73(4):954-62. PubMed ID: 6561202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contact activation of factor XI.
    Jacobs A; Mannhalter C; Margalit R; Schiffman S
    Br J Haematol; 1981 Sep; 49(1):77-86. PubMed ID: 7272231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new assay for high molecular weight kininogen in human plasma using a chromogenic substrate.
    Scott CF; Pixley RA; Colman RW
    Thromb Res; 1987 Dec; 48(6):685-700. PubMed ID: 3501619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stoichiometry of binding of high molecular weight kininogen to factor XI/XIa.
    Warn-Cramer BJ; Bajaj SP
    Biochem Biophys Res Commun; 1985 Dec; 133(2):417-22. PubMed ID: 3936495
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of arginine residues in the coagulant activity of high molecular weight kininogen.
    Chang JJ; Scott CF; Colman RW
    Blood; 1986 Mar; 67(3):805-10. PubMed ID: 3633200
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinetic analysis of the interaction of human tissue kallikrein with single-chain human high and low molecular weight kininogens.
    Maier M; Austen KF; Spragg J
    Proc Natl Acad Sci U S A; 1983 Jul; 80(13):3928-32. PubMed ID: 6575386
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of the procoagulant chain derived from human high molecular weight kininogen (Fitzgerald factor) by human tissue kallikrein.
    Maier M; Austen KF; Spragg J
    Blood; 1983 Aug; 62(2):457-63. PubMed ID: 6553501
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hageman factor-dependent pathways: mechanism of initiation and bradykinin formation.
    Kaplan AP
    Fed Proc; 1983 Nov; 42(14):3123-7. PubMed ID: 6556144
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies of binding of prekallikrein and Factor XI to high molecular weight kininogen and its light chain.
    Thompson RE; Mandle R; Kaplan AP
    Proc Natl Acad Sci U S A; 1979 Oct; 76(10):4862-6. PubMed ID: 291905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Studies on the effect of serine protease inhibitors on activated contact factors. Application in amidolytic assays for factor XIIa, plasma kallikrein and factor XIa.
    Tans G; Janssen-Claessen T; Rosing J; Griffin JH
    Eur J Biochem; 1987 May; 164(3):637-42. PubMed ID: 3552674
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interaction of type 1 plasminogen activator inhibitor with the enzymes of the contact activation system.
    Berrettini M; Schleef RR; España F; Loskutoff DJ; Griffin JH
    J Biol Chem; 1989 Jul; 264(20):11738-43. PubMed ID: 2787318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kininogenase activity of prostate-derived human glandular kallikrein (hK2) purified from seminal fluid.
    Charlesworth MC; Young CY; Miller VM; Tindall DJ
    J Androl; 1999; 20(2):220-9. PubMed ID: 10232657
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A monoclonal anti-human plasma prekallikrein antibody that inhibits activation of prekallikrein by factor XIIa on a surface.
    Veloso D; Silver LD; Hahn S; Colman RW
    Blood; 1987 Oct; 70(4):1053-62. PubMed ID: 2443201
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High molecular weight kininogen protects human plasma kallikrein and factor XIa against inactivation by plasma protease inhibitors.
    Schapira M; Scott CF; Colman RW
    Trans Assoc Am Physicians; 1981; 94():190-7. PubMed ID: 6979819
    [No Abstract]   [Full Text] [Related]  

  • 19. Functional characterization of human blood coagulation factor XIa using hybridoma antibodies.
    Sinha D; Koshy A; Seaman FS; Walsh PN
    J Biol Chem; 1985 Sep; 260(19):10714-9. PubMed ID: 3875611
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The so-called "contact" system of plasma: consequences of the activation of the Hageman factor].
    Damas J; Adam A
    Ann Biol Clin (Paris); 1988; 46(3):185-9. PubMed ID: 3044204
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.